Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 11 abstracts ...

Instead of a Cologuard version of the Sinatra standard, spots reference "Game of Thrones" and "Real Housewives." ...

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on EXAS stock, giving a Buy rating yesterday.Stay Ahead of the ...

Between now and March 7, fans can get a free ticket to Round 2 of the Cologuard Classic via a $5 donation to the Community Food Bank of Southern Arizona.

Exact Sciences stock crumbled Thursday on its growing rivalry with Guardant Health and Natera in colon cancer screening.

MADISON, Wis. - Exact Sciences Corp. (NASDAQ:EXAS), a leader in cancer screening and diagnostic tests with a market capitalization of $10 billion, announced clinical validation data for its ...

“At Exact Sciences, we’re committed to investing in our communities,” said Jake Orville, General Manager of Screening at Exact Sciences. “As the title sponsor of the Cologuard Classic, we’re proud to ...

Avanza Fonder AB purchased a new position in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) during the 4th quarter, ...

It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI.

The last 12 months saw major regulatory changes for the field of gastroenterology, from new FDA approvals to sweeping statewide and national legislation. Here is what to know about a handful of recent ...